A Phase II Study of Brentuximab Vedotin (BV) in the Treatment of Elderly Hodgkin Lymphoma (HL) Patients at First Relapse or With Primary Refractory Disease.
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2018
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms FIL BVHD01
- 08 Aug 2016 Planned primary completion date changed from 1 Mar 2016 to 1 Dec 2016.
- 19 Aug 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 01 Sep 2014 New trial record